Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Flowood, MS
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
St. Louis, MO
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Lincoln, NE
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Amherst, NY
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Amherst, NY
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Cedarhurst, NY
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Rochester, NY
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Durham, NC
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Pinehurst, NC
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Pinehurst, NC
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Dayton, OH
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Shaker Heights, OH
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Shaker Heights, OH
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Conshohocken, PA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Conshohocken, PA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Norristown, PA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Norristown, PA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Pheonixville, PA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Pheonixville, PA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Scranton, PA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Scranton, PA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Charleston, SC
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Memphis, TN
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Desoto, TX
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Desoto, TX
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Fort Worth, TX
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Irving, TX
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Irving, TX
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Petersburg, VA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Petersburg, VA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Spokane, WA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
mi
from
Vancouver,
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
mi
from
Vancouver,
Click here to add this to my saved trials
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
Status: Enrolling
Updated:  11/4/2015
VA - TN Valley Healthcare System
mi
from
Nashville, TN
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
Status: Enrolling
Updated: 11/4/2015
VA - TN Valley Healthcare System
mi
from
Nashville, TN
Click here to add this to my saved trials
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
Status: Enrolling
Updated:  11/4/2015
Salt Lake City VA
mi
from
Salt Lake City, UT
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
Status: Enrolling
Updated: 11/4/2015
Salt Lake City VA
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
Status: Enrolling
Updated:  11/4/2015
Puget Sound VA
mi
from
Seattle, WA
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care
Status: Enrolling
Updated: 11/4/2015
Puget Sound VA
mi
from
Seattle, WA
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
UCLA Neurology
mi
from
Los Angeles, CA
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
UCLA Neurology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
University of California at San Francisco
mi
from
San Francisco, CA
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
Washington University School of Medicine
mi
from
St Louis, MO
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
Washington University School of Medicine
mi
from
St Louis, MO
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
Columbia University Medical Center
mi
from
New York, NY
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
University of Rochester
mi
from
Rochester, NY
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
Ohio State University
mi
from
Columbus, OH
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
University of Texas Southwestern-Dallas
mi
from
Dallas, TX
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
University of Texas Southwestern-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated:  11/5/2015
University of Milan
mi
from
San Donato,
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide vs. Placebo for Periodic Paralysis
Status: Enrolling
Updated: 11/5/2015
University of Milan
mi
from
San Donato,
Click here to add this to my saved trials
Preventing Aggression in Veterans With Dementia
Preventing Aggression in Veterans With Dementia
Status: Enrolling
Updated:  11/5/2015
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Preventing Aggression in Veterans With Dementia
Preventing Aggression in Veterans With Dementia
Status: Enrolling
Updated: 11/5/2015
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Birmingham, AL
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Phoenix, AZ
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Little Rock, AR
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Denver, CO
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Bradenton, FL
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Melbourne, FL
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Melbourne, FL
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Atlanta, GA
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Baltimore, MD
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
New Hyde Park, NY
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Columbus, OH
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
West Jordan, UT
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Burlington, VT
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials